Particle Carriers for Combating Multidrug-Resistant Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Multidrug resistance (MDR) in tumors accounts for significant treatment failure. Particle carriers offer potential benefits for treating cancer, including the ability to target tumors and to deliver multiple cargo, providing opportunities to overcome drug resistance. In this Perspective, we provide a brief introduction to the MDR mechanisms and implications of tumor heterogeneity that contribute to drug resistance. We also highlight recent advances in the design of particles aimed at treating resistant tumors through particle-based codelivery of therapeutics. Finally, we discuss future directions, where an increased understanding of the tumor biology can be leveraged to develop new and improved particle-based cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801 · cited 2×
“As an example, the nucleotide excision repair (NER) pathway is the predominant mechanism that involves platinum-induced DNA damage.(8) Excision repair cross-complementing protein 1 (ERCC1) is the key component of the NER pathway.”
BackgroundTargeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 2×
“This phenomenon is commonly referred to as the multidrug resistance (MDR) of cancer.(3) The development of MDR contributes to significant treatment failure in patients with metastatic cancer.”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“The most well-known example is p53 mutations, which have been correlated with resistance to a spectrum of drugs.(11)”
BackgroundYasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · cited 1×
“When mutations occur at the drug binding sites of EGFR, these inhibitors become ineffective, leading to drug resistance.(10) In addition, disruption of apoptotic pathways, an important hallmark of cancer, can induce de novo drug resistance.”
Background
Cited by
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Self-citationBridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Self-citationLiao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 362
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors
Hettiarachchi, S. D., Graham, R. M., Mintz, K. J., Zhou, Y., Vanni, S., Peng, Z., & Leblanc, R. M. (2019) · Nanoscale · doi:10.1039/c8nr08970a · Cited by 294
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes
Pardo, J., Peng, Z., & Leblanc, R. (2018) · Molecules · doi:10.3390/molecules23020378 · Cited by 226
Du, L., Qin, H., Ma, T., Zhang, T., & Xing, D. (2017) · ACS Nano · doi:10.1021/acsnano.7b03226 · Cited by 181
Gao, W., Ye, G., Duan, X., Yang, X., & Yang, V. C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s115215 · Cited by 57
“Developing special drug delivery systems based on nanotechnology has attracted great attention in the treatment of cancers during the last decades.(3,4) Nanocarriers such as liposomes, micelles and nanoparticles can achieve tumor-targeted delivery due to the enhanced permeability and retention (EPR) effect, or tumor-s…”
Metadata
- Authors
- Yan, Y., Björnmalm, M., & Caruso, F.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-11-11
- Volume
- 7
- Issue
- 11
- Pages
- 9512-9517
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2328668678
- Cited by
- 89
- References
- 6
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.